Amgen Says Experimental Obesity Drug Has Promising Durability
Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.
Reuters Health Information
source https://www.medscape.com/viewarticle/984965?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/984965?src=rss
Comments
Post a Comment